Table of Contents
ISRN Hepatology
Volume 2014, Article ID 706945, 25 pages
http://dx.doi.org/10.1155/2014/706945
Review Article

Liver Transplantation for Hepatocellular Carcinoma beyond Milan Criteria: Multidisciplinary Approach to Improve Outcome

Department of Surgery, Klinikum rechts der Isar, Technical University Munich, Ismaningerstraße 22, D-81675 Munich, Germany

Received 15 December 2013; Accepted 3 January 2014; Published 4 March 2014

Academic Editors: I. Boin and L. Miele

Copyright © 2014 A. Kornberg. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Mittal and H. B. El-Serag, “Epidemiology of hepatocellular carcinoma: consider the population,” Journal of Clinical Gastroenterology, vol. 47, supplement, pp. S2–S6, 2013. View at Google Scholar
  2. F. X. Bosch, J. Ribes, M. Díaz, and R. Cléries, “Primary liver cancer: worldwide incidence and trends,” Gastroenterology, vol. 127, no. 5, supplemet 1, pp. S5–S16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Jemal, M. M. Center, C. DeSantis, and E. M. Ward, “Global patterns of cancer incidence and mortality rates and trends,” Cancer Epidemiology Biomarkers and Prevention, vol. 19, no. 8, pp. 1893–1907, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Bruix and M. Sherman, “Management of hepatocellular carcinoma: an update,” Hepatology, vol. 53, no. 3, pp. 1020–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. F. X. Bosch, J. Ribes, and J. Borràs, “Epidemiology of primary liver cancer,” Seminars in Liver Disease, vol. 19, no. 3, pp. 271–285, 1999. View at Google Scholar · View at Scopus
  6. H. B. El-Serag, “Hepatocellular carcinoma and hepatitis C in the United States,” Hepatology, vol. 36, no. 5, supplement 1, pp. S74–S83, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Llovet, A. Burroughs, and J. Bruix, “Hepatocellular carcinoma,” The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. E. J. Lim and J. Torresi, “Prevention of hepatitis C virus infection and liver cancer,” Recent Results Cancer Research, vol. 193, pp. 113–133, 2014. View at Google Scholar
  9. D. L. Thomas, “Global control of hepatitis C: where challenge meets opportunity,” Nature Medicine, vol. 19, no. 7, pp. 850–858, 2013. View at Google Scholar
  10. F. X. Bosch, J. Ribes, M. Díaz, and R. Cléries, “Primary liver cancer: worldwide incidence and trends,” Gastroenterology, vol. 127, supplement 1, pp. 5–16, 2004. View at Google Scholar
  11. S. van Meer, R. A. de Man, P. D. Siersema, and K. J. van Erpecum, “Surveillance for hepatocellular carcinoma in chronic liver disease: evidence and controversies,” World Journal of Gastroenterology, vol. 19, no. 40, pp. 6744–6756, 2013. View at Google Scholar
  12. G. L. Wong, H. L. Chan, Y. K. Tse et al., “On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir,” Hepatology, 2013. View at Publisher · View at Google Scholar
  13. P. Gopal, A. C. Yopp, A. K. Waljee et al., “Factors that affect accuracy of a-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis,” Clininical Gastroenterology and Hepatolology, 2013. View at Publisher · View at Google Scholar
  14. M. Ishii, H. Gama, N. Chida et al., “Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma,” The American Journal of Gastroenterology, vol. 95, no. 4, pp. 1036–1040, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Hwang, S. H. Kim, M. W. Lee et al., “Small (≤2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT,” British Journal of Radiology, vol. 85, no. 1015, pp. 314–322, 2012. View at Google Scholar
  16. J. A. Talwalkar and G. J. Gores, “Diagnosis and staging of hepatocellular carcinoma,” Gastroenterology, vol. 127, no. 5, supplemet 1, pp. S126–S132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. I. R. Kamel and D. A. Bluemke, “Imaging evaluation of hepatocellular carcinoma,” Journal of Vascular and Interventional Radiology, vol. 13, no. 9, pp. S173–S183, 2002. View at Google Scholar · View at Scopus
  18. A. Luciani, O. Allice, B. Zegai et al., “Imaging nodules within cirrhotic liver: how do I do it?” Journal de Radiologie, vol. 88, no. 7-8, pp. 1073–1090, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. do Song and S. H. Bae, “Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period,” Clininical and Molecular Hepatology, vol. 18, no. 3, pp. 258–267, 2012. View at Google Scholar
  20. I. Joo and B. I. Choi, “New paradigm for management of hepatocellular carcinoma by imaging,” Liver Cancer, vol. 1, no. 2, pp. 94–109, 2012. View at Google Scholar
  21. S. K. Venkatesh, V. Chandan, and L. R. Roberts, “Liver masses: a clinical, radiologic, and pathologic perspective,” Clininical Gastroenterology and Hepatology, 2013. View at Publisher · View at Google Scholar
  22. V. Zaydfudim, R. L. Smoot, C. J. Clark et al., “Role of operative therapy in non-cirrhotic patients with metastatic hepatocellular carcinoma,” Journal of Gastrointes-Tinal Surgery, vol. 16, no. 8, pp. 1516–1523, 2012. View at Google Scholar
  23. V. S. Yip, D. Gomez, C. Y. Tan et al., “Tumour size and differentiation predict survival after liver resection for hepatocellular carcinoma arising from non-cirrhotic and non-fibrotic liver: a case-controlled study,” International Journal of Surgery, vol. 13, pp. 1743–9191, 2013. View at Google Scholar
  24. B. Alkofer, V. Lepennec, and L. Chiche, “Hepatocellular cancer in the non-cirrhotic liver,” Journal of Visceral Surgery, vol. 148, no. 1, pp. 3–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. S. T. Fan, R. T. P. Poon, C. Yeung et al., “Outcome after partial hepatectomy for hepatocellular cancer within the Milan criteria,” British Journal of Surgery, vol. 98, no. 9, pp. 1292–1300, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Xu, L. Huang, B.-K. Li, Y.-Q. Zhang, J.-Q. Li, and Y.-F. Yuan, “Clinicopathologic features and long-term outcomes of Chinese patients with hepatocellular carcinoma in non-cirrhotic liver,” Digestive Surgery, vol. 25, no. 5, pp. 376–382, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Lang, G. C. Sotiropoulos, M. Dömland et al., “Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis,” British Journal of Surgery, vol. 92, no. 2, pp. 198–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Santambrogio, M. D. Kluger, M. Costa et al., “Hepatic resection for hepatocellular carcinoma in patients with Child-Pugh's A cirrhosis: is clinical evidence of portal hypertension a contraindication?” HPB, vol. 15, no. 1, pp. 78–84, 2013. View at Google Scholar
  29. G. Ercolani, G. L. Grazi, M. Ravaioli et al., “Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence,” Annals of Surgery, vol. 237, no. 4, pp. 536–543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Ikai, S. Arii, M. Kojiro et al., “Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey,” Cancer, vol. 101, no. 4, pp. 796–802, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. J. D. Wayne, G. Y. Lauwers, I. Ikai et al., “Preoperative predictors of survival after resection of small hepatocellular carcinomas,” Annals of Surgery, vol. 235, no. 5, pp. 722–730, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. R. Kianmanesh, J. M. Regimbeau, and J. Belghiti, “Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease,” Surgical Oncology Clinics of North America, vol. 12, no. 1, pp. 51–63, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. Z. Zheng, W. Liang, and D. P. Milgrom, “Liver transplantation versus liver resection in the treatment of hepatocellular carcinoma: a meta-analysis of observational studies,” Transplantation, vol. 97, no. 2, pp. 227–234, 2014. View at Google Scholar
  34. J. Shindoh, C. W. D Tzeng, and J. N. Vauthey, “Portal vein embolization for hepatocellular carcinoma,” Liver Cancer, vol. 1, no. 3-4, pp. 159–167, 2012. View at Google Scholar
  35. P. D. Peng, O. Hyder, M. Bloomston et al., “Sequential intra-arterial therapy and portal vein embolization is feasible and safe in patients with advanced hepatic malignancies,” HPB, vol. 14, no. 8, pp. 523–531, 2012. View at Google Scholar
  36. J. Shindoh, C. W. Tzeng, T. A. Aloia et al., “Safety and efficacy of portal vein embolization before planned major or extended hepatectomy: an institutional experience of 358 patients,” Journal of Gastrointestinal Surgery, vol. 18, no. 1, pp. 45–51, 2014. View at Google Scholar
  37. G. Torzilli, M. Garancini, M. Donadon, M. Cimino, F. Procopio, and M. Montorsi, “Intraoperative ultrasonographic detection of communicating veins between adjacent hepatic veins during hepatectomy for tumours at the hepatocaval confluence,” British Journal of Surgery, vol. 97, no. 12, pp. 1867–1873, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. H. Lang, “Liver resection—part II: operative procedure,” Chirurg, vol. 78, no. 9, pp. 849–866, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. H. Lang, “Liver resection—part I: anatomy and operative planning,” Chirurg, vol. 78, no. 8, pp. 761–774, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Li, J. S. Wu, X. T. Wang et al., “Major hepatectomy is a safe modality for the treatment of intrahepatic cholangiocarcinoma in selected patients complicated with cirrhosis,” Journal of Gastrointestinal Surgery, vol. 18, no. 1, pp. 194–199, 2014. View at Google Scholar
  41. M. M. Coolsen, E. M. Wong-Lun-Hing, R. M. van Dam et al., “A systematic review of outcomes in patients undergoing liver surgery in an enhanced recovery after surgery pathways,” HPB, vol. 15, no. 4, pp. 245–251, 2013. View at Google Scholar
  42. W. R. Jarnagin, M. Gonen, Y. Fong et al., “Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade,” Annals of Surgery, vol. 236, no. 4, pp. 397–407, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. J. Belghiti, K. Hiramatsu, S. Benoist, P. P. Massault, A. Sauvanet, and O. Farges, “Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection,” Journal of the American College of Surgeons, vol. 191, no. 1, pp. 38–46, 2000. View at Publisher · View at Google Scholar · View at Scopus
  44. S. Tanaka, Y. Iimuro, T. Hirano et al., “Safety of hepatic resection for hepatocellular carcinoma in obese patients with cirrhosis,” Surgery Today, vol. 43, no. 11, pp. 1290–1297, 2013. View at Google Scholar
  45. Y. Fong, R. L. Sun, W. Jarnagin, and L. H. Blumgart, “An analysis of 412 cases of hepatocellular carcinoma at a Western center,” Annals of Surgery, vol. 229, no. 6, pp. 790–799, 1999. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Belghiti, F. Regimbeau, F. Durand et al., “Resection of hepatocellular carcinoma: a European experience on 328 cases,” Hepato-Gastroenterology, vol. 49, no. 43, pp. 41–46, 2002. View at Google Scholar · View at Scopus
  47. T. Kanematsu, J. Furui, K. Yanaga, S. Okudaira, M. Shimada, and K. Shirabe, “A 16-year experience in performing hepatic resection in 303 patients with hepatocellular carcinoma: 1985–2000,” Surgery, vol. 131, no. 1, pp. S153–S158, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. R. T. Poon, S. T. Fan, C. M. Lo et al., “Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation,” Annals of Surgery, vol. 235, no. 3, pp. 373–382, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. J. M. Llovet, J. Fuster, and J. Bruix, “Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation,” Hepatology, vol. 30, no. 6, pp. 1434–1440, 1999. View at Google Scholar · View at Scopus
  50. M. Makuuchi, H. Hasegawa, and S. Yamazaki, “Indication of hepatectomy in patients with hepatocellular carcinoma and cirrhosis,” Shindan to Chiryo, vol. 74, pp. 1225–1230, 1986. View at Google Scholar
  51. S. Miyagawa, M. Makuuchi, S. Kawasaki, and T. Kakazu, “Criteria for safe hepatic resection,” The American Journal of Surgery, vol. 169, no. 6, pp. 589–594, 1995. View at Publisher · View at Google Scholar · View at Scopus
  52. J. Bruix, A. Castells, J. Bosch et al., “Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure,” Gastroenterology, vol. 111, no. 4, pp. 1018–1022, 1996. View at Google Scholar · View at Scopus
  53. I. Ikai, S. Arii, M. Kojiro et al., “Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey,” Cancer, vol. 101, no. 4, pp. 796–802, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. S. T. Fan, C. Mau Lo, R. T. P. Poon et al., “Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience,” Annals of Surgery, vol. 253, no. 4, pp. 745–758, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Mizuguchi, M. Kawamoto, M. Meguro et al., “Prognosis and predictors of surgical complications in hepatocellular carcinoma patients with or without cirrhosis after hepatectomy,” World Journal of Surgery, vol. 37, no. 6, pp. 1379–1387, 2013. View at Google Scholar
  56. H. Nathan, R. D. Schulick, M. A. Choti, and T. M. Pawlik, “Predictors of survival after resection of early hepatocellular carcinoma,” Annals of Surgery, vol. 249, no. 5, pp. 799–805, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Sala, A. Forner, M. Varela, and J. Bruix, “Prognostic prediction in patients with hepatocellular carcinoma,” Seminars in Liver Disease, vol. 25, no. 2, pp. 171–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. J. M. Llovet, “Updated treatment approach to hepatocellular carcinoma,” Journal of Gastroenterology, vol. 40, no. 3, pp. 225–235, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. Z. Z. Lin, W. Y. Shau, C. Hsu et al., “Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size,” PLoS ONE, vol. 8, no. 11, Article ID 80276, 2013. View at Google Scholar
  60. X. Qi, Y. Tang, D. An et al., “Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials,” Journal of Clinical Gastroenterology. In press.
  61. R. T.-P. Poon, K. K. C. Ng, C.-M. Lam, V. Ai, J. Yuen, and S.-T. Fan, “Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter,” Archives of Surgery, vol. 139, no. 3, pp. 281–287, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Sala, J. M. Llovet, R. Vilana et al., “Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma,” Hepatology, vol. 40, no. 6, pp. 1352–1360, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Takahashi, M. Kudo, H. Chung et al., “Initial treatment response is essential to improve survival in patients with hepatocellular carcinoma who underwent curative radiofrequency ablation therapy,” Oncology, vol. 72, supplement 1, pp. 98–103, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Lee Cheah and P. Chow, “Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies,” Liver Cancer, vol. 1, no. 3-4, pp. 183–189, 2012. View at Google Scholar
  65. P.-A. Clavien, M. Lesurtel, P. M. Bossuyt, G. J. Gores, B. Langer, and A. Perrier, “Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report,” The Lancet Oncology, vol. 13, no. 1, pp. e11–e22, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. M. W. Welker, W. O. Bechstein, S. Zeuzem, and J. Trojan, “Recurrent hepatocellular carcinoma after liver transplantation—an emerging clinical challenge,” Transplantation International, vol. 26, no. 2, pp. 109–118, 2012. View at Google Scholar
  67. T. E. Starzl, G. B. G. Klintmalm, and K. A. Porter, “Liver transplantation with use of cyclosporin A and prednisone,” The New England Journal of Medicine, vol. 305, no. 5, pp. 266–269, 1981. View at Google Scholar · View at Scopus
  68. S. Iwatsuki, R. D. Gordon, B. W. Shaw Jr., and T. E. Starzl, “Role of liver transplantation in cancer therapy,” Annals of Surgery, vol. 202, no. 4, pp. 401–407, 1985. View at Google Scholar · View at Scopus
  69. S. Iwatsuki, T. E. Starzl, D. G. Sheahan et al., “Hepatic resection versus transplantation for hepatocellular carcinoma,” Annals of Surgery, vol. 214, no. 3, pp. 221–229, 1991. View at Google Scholar · View at Scopus
  70. S. Iwatsuki and T. E. Starzl, “Role of liver transplantation in the treatment of hepatocellular carcinoma,” Seminars in Surgical Oncology, vol. 9, no. 4, pp. 337–340, 1993. View at Google Scholar · View at Scopus
  71. R. Pichlmayr, A. Weimann, G. Steinhoff, and B. Ringe, “Liver transplantation for hepatocellular carcinoma: clinical results and future aspects,” Cancer Chemotherapy and Pharmacology, vol. 31, no. 1, supplement, pp. S157–S161, 1992. View at Publisher · View at Google Scholar · View at Scopus
  72. B. Ringe, R. Pichlmayr, C. Wittekind, and G. Tusch, “Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients,” World Journal of Surgery, vol. 15, no. 2, pp. 270–285, 1991. View at Google Scholar · View at Scopus
  73. M. J. Stone, J. M. Fulmer, and G. B. Klintmalm, “Transplantation for primary hepatic malignancy,” in Transplantation of the Liver, R. W. Busuttil and G. B. Klintmalm, Eds., pp. 211–232, Saunders, Philadelphia, Pa, USA, 2nd edition, 2005. View at Google Scholar
  74. H. Bismuth, L. Chiche, R. Adam, D. Castaing, T. Diamond, and A. Dennison, “Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients,” Annals of Surgery, vol. 218, no. 2, pp. 145–151, 1993. View at Google Scholar · View at Scopus
  75. V. Mazzaferro, E. Regalia, R. Doci et al., “Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis,” The New England Journal of Medicine, vol. 334, no. 11, pp. 693–699, 1996. View at Publisher · View at Google Scholar · View at Scopus
  76. R. Kakodkar and A. S. Soin, “Liver Transplantation for HCC: a review,” Indian Journal of Surgery, vol. 74, no. 1, pp. 100–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. T. M. Earl and W. C. Chapman, “Transplantation for hepatocellular carcinoma: the North American experience,” Recent Results of Cancer Research, vol. 190, pp. 145–164, 2013. View at Google Scholar
  78. J. R. L. Maggs, A. R. Suddle, V. Aluvihare, and M. A. Heneghan, “Systematic review: the role of liver transplantation in the management of hepatocellular carcinoma,” Alimentary Pharmacology and Therapeutics, vol. 35, no. 10, pp. 1113–1134, 2012. View at Publisher · View at Google Scholar · View at Scopus
  79. M. F. Silva and M. Sherman, “Criteria for liver transplantation for HCC: what should the limits be?” Journal of Hepatology, vol. 55, no. 5, pp. 1137–1147, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. J. I. Herrero, B. Sangro, F. Pardo et al., “Liver transplantation in patients with hepatocellular carcinoma across Milan criteria,” Liver Transplantation, vol. 14, no. 3, pp. 272–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Silva, A. Moya, M. Berenguer et al., “Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma,” Liver Transplantation, vol. 14, no. 10, pp. 1449–1460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. V. Mazzaferro, S. Bhoori, C. Sposito et al., “Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience,” Liver Transplantation, vol. 17, supplement S2, pp. S44–S57, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. M. de Giorgio, S. Vezzoli, E. Cohen et al., “Prediction of progression-free survival in patients presenting with hepatocellular carcinoma within the Milan criteria,” Liver Transplantation, vol. 16, no. 4, pp. 503–512, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. S. Jonas, W. O. Bechstein, T. Steinmüller et al., “Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis,” Hepatology, vol. 33, no. 5, pp. 1080–1086, 2001. View at Publisher · View at Google Scholar · View at Scopus
  85. Y. Ishizaki and S. Kawasaki, “The evolution of liver transplantation for hepatocellular carcinoma (past, present, and future),” Journal of Gastroenterology, vol. 43, no. 1, pp. 18–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  86. R. Koschny, J. Schmidt, and T. M. Ganten, “Beyond Milan criteria—chances and risks of expanding transplantation criteria for HCC patients with liver cirrhosis,” Clinical Transplantation, vol. 23, supplement s21, pp. 49–60, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. P. Sauer, T. W. Kraus, P. Schemmer et al., “Liver transplantation for hepatocellular carcinoma: is there evidence for expanding the selection criteria?” Transplantation, vol. 80, no. 1S, pp. S105–S108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  88. F. Y. Yao, L. Ferrell, N. M. Bass et al., “Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival,” Hepatology, vol. 33, no. 6, pp. 1394–1403, 2001. View at Publisher · View at Google Scholar · View at Scopus
  89. J. I. Herrero, B. Sangro, J. Quiroga et al., “Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma,” Liver Transplantation, vol. 7, no. 7, pp. 631–636, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Löhe, M. K. Angele, A. L. Gerbes, U. Löhrs, K.-W. Jauch, and R. J. Schauer, “Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma,” European Journal of Surgical Oncology, vol. 31, no. 9, pp. 994–999, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. F. Löhe, M. K. Angele, M. Rentsch et al., “Multifocal manifestation does not affect vascular invasion of hepatocellular carcinoma: implications for patient selection in liver transplantation,” Clinical Transplantation, vol. 21, no. 6, pp. 696–701, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. J. P. Duffy, A. Vardanian, E. Benjamin et al., “Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA,” Annals of Surgery, vol. 246, no. 3, pp. 502–509, 2007. View at Publisher · View at Google Scholar · View at Scopus
  93. R. T. P. Poon, S. T. Fan, C. M. Lo, C. L. Liu, and J. Wong, “Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival,” Annals of Surgery, vol. 245, no. 1, pp. 51–58, 2007. View at Publisher · View at Google Scholar · View at Scopus
  94. U. Cillo, A. Vitale, M. Bassanello et al., “Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma,” Annals of Surgery, vol. 239, no. 2, pp. 150–159, 2004. View at Publisher · View at Google Scholar · View at Scopus
  95. T. Ito, Y. Takada, M. Ueda et al., “Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation,” Liver Transplantation, vol. 13, no. 12, pp. 1637–1644, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. S.-G. Lee, S. Hwang, D.-B. Moon et al., “Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center,” Liver Transplantation, vol. 14, no. 7, pp. 935–945, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. J. I. Herrero, B. Sangro, F. Pardo et al., “Liver transplantation in patients with hepatocellular carcinoma across Milan criteria,” Liver Transplantation, vol. 14, no. 3, pp. 272–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. V. Mazzaferro, J. M. Llovet, R. Miceli et al., “Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis,” The Lancet Oncology, vol. 10, no. 1, pp. 35–43, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. F. Muscari, B. Foppa, N. Kamar, J. M. Peron, J. Selves, and B. Suc, “Liberal selection criteria for liver transplantation for hepatocellular carcinoma,” British Journal of Surgery, vol. 96, no. 7, pp. 785–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. D. DuBay, C. Sandroussi, L. Sandhu et al., “Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion,” Annals of Surgery, vol. 253, no. 1, pp. 166–172, 2011. View at Publisher · View at Google Scholar · View at Scopus
  101. H. Y. Yoo, C. H. Patt, J.-F. Geschwind, and P. J. Thuluvath, “The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1987 and 2001: 5-Year survival has improved significantly with time,” Journal of Clinical Oncology, vol. 21, no. 23, pp. 4329–4335, 2003. View at Publisher · View at Google Scholar · View at Scopus
  102. A. C. Chan, S. T. Fan, R. T. Poon et al., “Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system,” HPB, vol. 15, no. 6, pp. 39–48, 2013. View at Google Scholar
  103. A. B. Massie, B. Caffo, S. E. Gentry et al., “MELD exceptions and rates of waiting list outcomes,” The American Journal of Transplantation, vol. 11, no. 11, pp. 2362–2371, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. G. N. Ioannou, J. D. Perkins, and R. L. Carithers Jr., “Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival,” Gastroenterology, vol. 134, no. 5, pp. 1342–1351, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. P. Sharma, V. Balan, J. L. Hernandez et al., “Liver transplantation for hepatocellular carcinoma: the MELD impact,” Liver Transplantation, vol. 10, no. 1, pp. 36–41, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. J. Roma, E. Balbi, L. Pacheco-Moreira et al., “Impact of model for end-stage liver disease score on long-term survival following liver transplantation for hepatocellular carcinoma,” Transplantation Proceedings, vol. 44, no. 8, pp. 423–427, 2012. View at Google Scholar
  107. S. Hwang, S.-G. Lee, and J. Belghiti, “Liver transplantation for HCC: its role. Eastern and Western perspectives,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 17, no. 4, pp. 443–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Adler, F. de Pauw, P. Vereerstraeten et al., “Outcome of patients with hepatocellular carcinoma listed for liver transplantation within the Eurotransplant allocation system,” Liver Transplantation, vol. 14, no. 4, pp. 526–533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. P. Schemmer, A. Nickkholgh, T. Gerling, J. Weitz, M. W. Büchler, and J. Schmidt, “Rescue allocation for liver transplantation within Eurotransplant: the Heidelberg experience,” Clinical Transplantation, vol. 23, supplement s21, pp. 42–48, 2009. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Bhoori, C. Sposito, A. Germini, J. Coppa, and V. Mazzaferro, “The challenges of liver transplantation for hepatocellular carcinoma on cirrhosis,” Transplant International, vol. 23, no. 7, pp. 712–722, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. A. Giorgio, G. Calisti, A. Di Sarno et al., “Characterization of dysplastic nodules, early hepatocellular carcinoma and progressed hepatocellular carcinoma in cirrhosis with contrast-enhanced ultrasound,” Anticancer Research, vol. 31, no. 11, pp. 3977–3982, 2011. View at Google Scholar · View at Scopus
  112. J. W. Marsh, I. Dvorchik, and S. Iwatsuki, “Liver transplantation in the treatment of hepatocellular carcinoma,” Journal of Hepato-Biliary-Pancreatic Surgery, vol. 5, no. 1, pp. 24–28, 1998. View at Google Scholar · View at Scopus
  113. S.-S. Zheng, X. Xu, J. Wu et al., “Liver transplantation for hepatocellular carcinoma: Hangzhou experiences,” Transplantation, vol. 85, no. 12, pp. 1726–1732, 2008. View at Publisher · View at Google Scholar · View at Scopus
  114. N. M. Kneteman, J. Oberholzer, M. Al Saghier et al., “Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma,” Liver Transplantation, vol. 10, no. 10, pp. 1301–1311, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. N. Onaca, G. L. Davis, R. M. Goldstein, L. W. Jennings, and G. B. Klintmalm, “Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the international registry of hepatic tumors in liver transplantation,” Liver Transplantation, vol. 13, no. 3, pp. 391–399, 2007. View at Publisher · View at Google Scholar · View at Scopus
  116. S. S. Patel, A. K. Arrington, and S. McKenzie, “Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States,” International Journal of Hepatology, vol. 2012, Article ID 253517, 7 pages, 2012. View at Publisher · View at Google Scholar
  117. J. Bruix, J. Fuster, and J. M. Llovet, “Liver transplantation for hepatocellular carcinoma: foucault pendulum versus evidence-based decision,” Liver Transplantation, vol. 9, no. 7, pp. 700–702, 2003. View at Publisher · View at Google Scholar · View at Scopus
  118. T. Unek, S. Karademir, N. C. Arslan et al., “Comparison of Milan and UCSF criteria for liver transplantation to treat hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 17, no. 37, pp. 4206–4212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. V. Mazzaferro, Y. S. Chun, R. T. P. Poon et al., “Liver transplantation for hepatocellular carcinoma,” Annals of Surgical Oncology, vol. 15, no. 4, pp. 1001–1007, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. T. Decaens, F. Roudot-Thoraval, S. Hadni-Bresson et al., “Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time,” Liver Transplantation, vol. 12, no. 12, pp. 1761–1769, 2006. View at Publisher · View at Google Scholar · View at Scopus
  121. F. Y. Yao, L. Xiao, N. M. Bass, R. Kerlan, N. L. Ascher, and J. P. Roberts, “Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging,” The American Journal of Transplantation, vol. 7, no. 11, pp. 2587–2596, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. U. Cillo, A. Vitale, F. Grigoletto et al., “Intention-to-treat analysis of liver transplantation in selected, aggressively treated HCC patients exceeding the Milan criteria,” The American Journal of Transplantation, vol. 7, no. 4, pp. 972–981, 2007. View at Publisher · View at Google Scholar · View at Scopus
  123. K. T. Lopez, S. K. Kuwada, and L. L. Wong, “Consequences of needle tract seeding of hepatocellular cancer after liver transplant,” Clinical Transplantation, vol. 27, no. 4, pp. 400–406, 2013. View at Google Scholar
  124. J. D. Perkins, “Seeding risk following percutaneous approach to hepatocellular carcinoma,” Liver Transplantation, vol. 13, no. 11, pp. 1603–1607, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. R. Stigliano, L. Marelli, D. Yu, N. Davies, D. Patch, and A. K. Burroughs, “Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome?. Seeding risk for percutaneous approach of HCC,” Cancer Treatment Reviews, vol. 33, no. 5, pp. 437–447, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. W. C. Zhao, L. F. Fan, N. Yang et al., “Preoperative predictors of microvascular invasion in multinodular hepatocellular carcinoma,” European Journal of Surgical Oncology, vol. 39, no. 8, pp. 858–864, 2013. View at Google Scholar
  127. A. Kornberg, U. Witt, B. Küpper et al., “Postinterventional tumor necrosis predicts recurrence-free long-term survival in liver transplant patients with advanced hepatocellular carcinoma,” Transplantation Proceedings, vol. 35, no. 5, pp. 1913–1915, 2013. View at Google Scholar
  128. Y. Nagano, H. Shimada, K. Takeda et al., “Predictive factors of microvascular invasion in patients with hepatocellular carcinoma larger than 5 cm,” World Journal of Surgery, vol. 32, no. 10, pp. 2218–2222, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. C. D. Witjes, F. E. Willemssen, J. Verheij et al., “Histological differentiation grade and microvascular invasion of hepatocellular carcinoma predicted by dynamic contrast-enhanced MRI,” Journal of Magnetic Resonance Imaging, vol. 36, no. 7, pp. 641–647, 2012. View at Google Scholar
  130. H. Chandarana, E. Robinson, C. H. Hajdu, L. Drozhinin, J. S. Babb, and B. Taouli, “Microvascular invasion in hepatocellular carcinoma: is it predictable with pretransplant MRI?” The American Journal of Roentgenology, vol. 196, no. 5, pp. 1083–1089, 2011. View at Publisher · View at Google Scholar · View at Scopus
  131. S. H. Yang, K. S. Suh, H. W. Lee et al., “The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients,” Liver Transplanatation, vol. 12, no. 11, pp. 1655–1660, 2006. View at Google Scholar
  132. A. Kornberg, M. Freesmeyer, E. Bärthel et al., “18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients,” The American Journal of Transplantation, vol. 9, no. 3, pp. 592–600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. J. W. Lee, J. C. Paeng, K. W. Kang et al., “Prediction of tumor recurrence by18F-FDG PET in liver transplantation for hepatocellular carcinoma,” Journal of Nuclear Medicine, vol. 50, no. 5, pp. 682–687, 2009. View at Publisher · View at Google Scholar · View at Scopus
  134. A. Kornberg, B. Küpper, K. Thrum et al., “Increased 18F-FDG uptake of hepatocellular carcinoma on positron emission tomography independently predicts tumor recurrence in liver transplant patients,” Transplantation Proceedings, vol. 41, no. 6, pp. 2561–2563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. A. Kornberg, B. Küpper, A. Tannapfel et al., “Patients with non-[18F]fludeoxyglucose-avid advanced hepatocellular carcinoma on clinical staging may achieve long-term recurrence-free survival after liver transplantation,” Liver Transplantation, vol. 18, no. 1, pp. 53–61, 2012. View at Publisher · View at Google Scholar · View at Scopus
  136. S. D. Lee, S. H. Kim, Y. K. Kim et al., “(18)F-FDG-PET/CT predicts early tumor recurrence in living donor liver transplantation for hepatocellular carcinoma,” Transplant International, vol. 26, no. 1, pp. 50–60, 2013. View at Google Scholar
  137. G. Tomasi and E. O. Aboagye, “Introduction to the analysis of PET data in oncology,” Journal of Pharmacokinetics and Pharmacodynamics, vol. 40, no. 4, pp. 419–436, 2013. View at Google Scholar
  138. K. Shirabe, S. Itoh, T. Yoshizumi et al., “The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma—with special reference to the serum levels of des-gamma-carboxy prothrombin,” Journal of Surgical Oncology, vol. 95, no. 3, pp. 235–240, 2007. View at Publisher · View at Google Scholar · View at Scopus
  139. M. Fujiki, Y. Takada, Y. Ogura et al., “Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma,” The American Journal of Transplantation, vol. 9, no. 10, pp. 2362–2371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. T. Kaido, K. Ogawa, A. Mori et al., “Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma,” Surgery, vol. 154, no. 5, pp. 1053–1560, 2013. View at Google Scholar
  141. W. J. Ma, H. Y. Wang, and L. S. Teng, “Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy,” World Journal of Surgical Oncology, vol. 11, no. 1, article 212, 2013. View at Google Scholar
  142. F. Hirokawa, M. Hayashi, Y. Miyamoto et al., “Outcomes and predictors of microvascular invasion of solitary hepatocellular carcinoma,” Hepatology Research, 2013. View at Publisher · View at Google Scholar
  143. S. Kiriyama, K. Uchiyama, M. Ueno et al., “Triple positive tumor markers for hepatocellular carcinoma are useful predictors of poor survival,” Annals of Surgery, vol. 254, no. 6, pp. 984–991, 2011. View at Publisher · View at Google Scholar · View at Scopus
  144. Q. Lai, A. W. Avolio, I. Graziadei et al., “Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation,” Liver Transplantation, vol. 19, no. 10, pp. 1108–1118, 2013. View at Google Scholar
  145. C. D. Witjes, W. G. Polak, C. Verhoef et al., “Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers,” Digestive Surgery, vol. 29, no. 6, pp. 522–528, 2012. View at Google Scholar
  146. L. L. Wong, W. E. Naugler, J. Schwartz et al., “Impact of locoregional therapy and alpha-fetoprotein on outcomes in transplantation for liver cancer: a UNOS Region 6 pooled analysis,” Clinical Transplantation, vol. 27, no. 1, pp. 72–79, 2013. View at Google Scholar
  147. T. C. Dumitra, S. Dumitra, P. P. Metrakos et al., “Pretransplantation α-fetoprotein slope and Milan criteria: strong predictors of hepatocellular carcinoma recurrence after transplantation,” Transplantation, vol. 95, no. 1, pp. 228–233, 2013. View at Google Scholar
  148. Q. Lai, F. Melandro, R. S. Pinheiro et al., “Alpha-fetoprotein and novel tumor biomarkers as predictors of hepatocellular carcinoma recurrence after surgery: a brilliant star raises again,” International Journal of Hepatology, vol. 2012, Article ID 893103, 9 pages, 2012. View at Publisher · View at Google Scholar
  149. K. Berry and G. N. Ioannou, “Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma,” Liver Transplantation, vol. 19, no. 6, pp. 634–645, 2013. View at Google Scholar
  150. S. H. Yang, K.-S. Suh, H. W. Lee et al., “A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma,” Surgery, vol. 141, no. 5, pp. 598–609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  151. O. Ciccarelli, Q. Lai, P. Goffette et al., “Liver transplantation for hepatocellular cancer: UCL experience in 137 adult cirrhotic patients. Alpha-foetoprotein level and locoregional treatment as refined selection criteria,” Transplant International, vol. 25, no. 8, pp. 867–875, 2012. View at Google Scholar
  152. H. S. Heinzow, J. G. Brockmann, M. Köhler et al., “Liver transplantation versus supraselective transarterial chemoembolization in palliative patients with hepatocellular carcinoma exceeding the Milan Criteria—is it time for a more individual approach?” Annals of Transplantation, vol. 18, pp. 515–524, 2013. View at Google Scholar
  153. S. Merani, P. Majno, N. M. Kneteman et al., “The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma,” Journal of Hepatology, vol. 55, no. 4, pp. 814–819, 2011. View at Publisher · View at Google Scholar · View at Scopus
  154. G. J. Guthrie, K. A. Charles, C. S. Roxburgh et al., “The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer,” Critical Reviews in Oncology/Hematology, vol. 88, no. 1, pp. 218–230, 2013. View at Google Scholar
  155. M. Ham and A. Moon, “Inflammatory and microenvironmental factors involved in breast cancer progression,” Archieves of Pharmacal Research, vol. 36, no. 12, pp. 1419–1431, 2013. View at Google Scholar
  156. D. Laveti, M. Kumar, R. Hemalatha et al., “Anti-inflammatory treatments for chronic diseases: a review,” Inflammation Allergy and Drug Targets, vol. 12, no. 5, pp. 349–361, 2013. View at Google Scholar
  157. M. E. McNally, A. Martinez, H. Khabiri et al., “Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization,” Annals of Surgical Oncology, vol. 20, no. 3, pp. 923–928, 2013. View at Google Scholar
  158. D. J. Pinato and R. Sharma, “An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma,” Translational Research, vol. 160, no. 2, pp. 146–152, 2012. View at Google Scholar
  159. M. Ishizuka, K. Kubota, J. Kita, M. Shimoda, M. Kato, and T. Sawada, “Usefulness of a modified inflammation-based prognostic system for predicting postoperative mortality of patients undergoing surgery for primary hepatocellular carcinoma,” Journal of Surgical Oncology, vol. 103, no. 8, pp. 801–806, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. K. J. Halazun, M. A. Hardy, A. A. Rana et al., “Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma,” Annals of Surgery, vol. 250, no. 1, pp. 141–151, 2009. View at Google Scholar
  161. Q. Lai, E. Castro Santa, and J. M. Rico Juri, “Neutrophil and platelet-to-lymphocyte ratio as new predictors of dropout and recurrence after liver transplantation for hepatocellular cancer,” Transpl International, vol. 27, no. 1, pp. 32–41, 2014. View at Publisher · View at Google Scholar
  162. J. W. Jang, B. S. Oh, J. H. Kwon et al., “Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma,” Cytokine, vol. 60, no. 3, pp. 686–693, 2012. View at Google Scholar
  163. H. J. An, J. W. Jang, S. H. Bae et al., “Serum C-reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma,” Liver Transplantation, vol. 18, no. 12, pp. 1406–1414, 2012. View at Google Scholar
  164. W. Sieghart, M. Pinter, F. Hucke et al., “Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma,” Hepatology, vol. 57, no. 6, pp. 2224–2234, 2013. View at Google Scholar
  165. N. Imai, A. Kinoshita, H. Onoda et al., “Persistent elevated C-reactive protein after treatment is an independent marker of a poor prognosis in patients with hepatocellular carcinoma,” Clinical and Translational Oncology, vol. 15, no. 7, pp. 575–581, 2013. View at Google Scholar
  166. H. Shiba, K. Furukawa, Y. Fujiwara et al., “Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma,” Anticancer Research, vol. 33, no. 2, pp. 705–709, 2013. View at Google Scholar
  167. H. Nishikawa, A. Arimoto, T. Wakasa et al., “Pre-treatment C-reactive protein as a prognostic factor for recurrence after surgical resection of hepatocellular carcinoma,” Anticancer Research, vol. 33, no. 3, pp. 1181–1188, 2013. View at Google Scholar
  168. Z. Zheng, L. Zhou, S. Gao et al., “Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis,” International Journal of Medical Science, vol. 10, no. 6, pp. 653–664, 2013. View at Google Scholar
  169. C. H. Jun, H. S. Ki, K. H. Lee et al., “Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE,” Clinical and Molecular Hepatology, vol. 19, no. 1, pp. 70–77, 2013. View at Publisher · View at Google Scholar
  170. E. R. Lemmer, S. L. Friedman, and J. M. Llovet, “Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling,” Seminars in Liver Disease, vol. 26, no. 4, pp. 373–384, 2006. View at Publisher · View at Google Scholar · View at Scopus
  171. D. Kong, H. Chen, W. Chen et al., “Gene expression profiling analysis of hepatocellular carcinoma,” European Journal of Medical Research, vol. 14, no. 1, article 44, 2013. View at Google Scholar
  172. T. Utsunomiya, D. Ishikawa, M. Asanoma et al., “Specific miRNA expression profiles of non-tumor liver tissue predict a risk for recurrence of hepatocellular carcinoma,” Hepatology Research, 2013. View at Publisher · View at Google Scholar
  173. Y. L. Wang, Z. J. Zhu, D. H. Teng et al., “Glypican-3 expression and its relationship with recurrence of HCC after liver transplantation,” World Journal of Gastroenterology, vol. 18, no. 19, pp. 2408–2414, 2012. View at Google Scholar
  174. M. Schwartz, I. Dvorchik, S. Roayaie et al., “Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers,” Journal of Hepatology, vol. 49, no. 4, pp. 581–588, 2008. View at Publisher · View at Google Scholar · View at Scopus
  175. V. R. Mas, R. A. Fisher, K. J. Archer et al., “Genes associated with progression and recurrence of hepatocellular carcinoma in hepatitis C patients waiting and undergoing liver transplantation: preliminary results,” Transplantation, vol. 83, no. 7, pp. 973–981, 2007. View at Publisher · View at Google Scholar · View at Scopus
  176. S. Jonas, H. Al-Abadi, C. Benckert et al., “Prognostic significance of the dna-index in liver transplantation for hepatocellular carcinoma in cirrhosis,” Annals of Surgery, vol. 250, no. 6, pp. 1008–1013, 2009. View at Publisher · View at Google Scholar · View at Scopus
  177. J. T. Heckman, M. B. Devera, J. W. Marsh et al., “Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation,” Annals of Surgical Oncology, vol. 15, no. 11, pp. 3169–3177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  178. M. Fujiki, F. Aucejo, and R. Kim, “General overview of neo-adjuvant therapy for hepatocellular carcinoma before liver transplantation: necessity or option?” Liver International, vol. 31, no. 8, pp. 1081–1089, 2011. View at Google Scholar · View at Scopus
  179. M. Cescon, A. Cucchetti, M. Ravaioli, and A. D. Pinna, “Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate,” Journal of Hepatology, vol. 58, no. 3, pp. 609–618, 2013. View at Google Scholar
  180. H. Nishikawa, T. Kimura, R. Kita, and Y. Osaki, “Radiofrequency ablation for hepatocellular carcinoma,” International Journal of Hyperthermia, vol. 29, no. 6, pp. 558–568, 2013. View at Google Scholar
  181. W. C. Chapman, M. B. Majella Doyle, J. E. Stuart et al., “Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation,” Annals of Surgery, vol. 248, no. 4, pp. 617–625, 2008. View at Publisher · View at Google Scholar · View at Scopus
  182. R. Kim, A. Tan, B. Estfan, and F. Aucejo, “Adjuvant treatment after orthotopic liver transplantation: is it really necessary?” Oncology, vol. 23, no. 14, pp. 1276–1281, 2009. View at Google Scholar · View at Scopus
  183. A. Coilly, B. Roche, and D. Samuel, “Current management and perspectives for HCV recurrence after liver transplantation,” Liver International, vol. 33, supplement 1, pp. 56–62, 2013. View at Google Scholar
  184. D. Samuel, “The option of liver transplantation for hepatitis B: where are we?” Digestive and Liver Disease, vol. 41, supplement 2, pp. S185–S189, 2009. View at Publisher · View at Google Scholar · View at Scopus
  185. J. Campsen, M. Zimmermann, J. Trotter et al., “Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States with hepatitis B immunoglobulin and nucleoside/nucleotide analogues,” Liver Transplantation, vol. 19, no. 9, pp. 1020–1129, 2013. View at Google Scholar
  186. B. E. Fortune, V. Umman, T. Gilliland, and S. Emre, “Liver transplantation for hepatocellular carcinoma: a surgical perspective,” Journal of Clinical Gastroenterology, vol. 47, supplement, pp. 37–42, 2013. View at Google Scholar
  187. M. E. Facciuto, C. Rochon, M. Pandey et al., “Surgical dilemma: liver resection or liver transplantation for hepatocellular carcinoma and cirrhosis. Intention-to-treat analysis in patients within and outwith Milan criteria,” HPB, vol. 11, no. 5, pp. 398–404, 2009. View at Publisher · View at Google Scholar · View at Scopus
  188. D. L. Chan, N. A. Alzahrani, D. L. Morris, and T. C. Chua, “Systematic review of efficacy and outcomes of salvage liver transplantation after primary hepatic resection for hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 29, no. 1, pp. 31–41, 2014. View at Publisher · View at Google Scholar
  189. P. E. Majno, F. P. Sarasin, G. Mentha, and A. Hadengue, “Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcome-oriented decision analysis,” Hepatology, vol. 31, no. 4, pp. 899–906, 2000. View at Google Scholar · View at Scopus
  190. J. Belghiti, A. Cortes, E. K. Abdalla et al., “Resection prior to liver transplantation for hepatocellular carcinoma,” Annals of Surgery, vol. 238, no. 6, pp. 885–893, 2003. View at Google Scholar · View at Scopus
  191. J. Belghiti, B. I. Carr, P. D. Greig, R. Lencioni, and R. T. Poon, “Treatment before liver transplantation for HCC,” Annals of Surgical Oncology, vol. 15, no. 4, pp. 993–1000, 2008. View at Publisher · View at Google Scholar · View at Scopus
  192. S. Hwang, S.-G. Lee, D.-B. Moon et al., “Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma,” Liver Transplantation, vol. 13, no. 5, pp. 741–746, 2007. View at Publisher · View at Google Scholar · View at Scopus
  193. M. del Gaudio, G. Ercolani, M. Ravaioli et al., “Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: university of Bologna experience,” The American Journal of Transplantation, vol. 8, no. 6, pp. 1177–1185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  194. R. Adam, D. Azoulay, D. Castaing et al., “Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?” Annals of Surgery, vol. 238, no. 4, pp. 508–518, 2003. View at Google Scholar · View at Scopus
  195. D. Fuks, S. Dokmak, V. Paradis, M. Diouf, F. Durand, and J. Belghiti, “Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis,” Hepatology, vol. 55, no. 1, pp. 132–140, 2012. View at Publisher · View at Google Scholar · View at Scopus
  196. M. E. Facciuto, B. Koneru, J. P. Rocca et al., “Surgical treatment of hepatocellular carcinoma beyond Milan criteria. Results of liver resection, salvage transplantation, and primary liver transplantation,” Annals of Surgical Oncology, vol. 15, no. 5, pp. 1383–1391, 2008. View at Publisher · View at Google Scholar · View at Scopus
  197. Z. Hu, J. Zhou, X. Xu et al., “Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection,” PLoS ONE, vol. 7, no. 5, Article ID e36587, 2012. View at Publisher · View at Google Scholar · View at Scopus
  198. F. Liu, Y. Wei, W. Wang et al., “Salvage liver transplantation for recurrent hepatocellular carcinoma within UCSF criteria after liver resection,” PLoS ONE, vol. 7, no. 11, Article ID e48932, 2012. View at Google Scholar
  199. H. Y. Li, Y. G. Wei, L. N. Yan, and B. Li, “Salvage liver transplantation in the treatment of hepatocellular carcinoma: a meta-analysis,” World Journal of Gastroenterology, vol. 18, no. 19, pp. 2415–2422, 2012. View at Google Scholar
  200. Z. Hu, W. Wang, Z. Li, S. Ye, and S. S. Zheng, “Recipient outcomes of salvage liver transplantation versus primary liver transplantation: a systematic review and meta-analysis,” Liver Transplantation, vol. 18, no. 11, pp. 1316–1323, 2012. View at Google Scholar
  201. J. A. Marrero, “Multidisciplinary management of hepatocellular carcinoma: where are we today?” Seminars in Liver Disease, vol. 33, supplement 1, pp. 3–10, 2013. View at Google Scholar
  202. A. Shrimal, M. Prasanth, and A. V. Kulkarni, “Interventional radiological treatment of hepatocellular carcinoma: an update,” Indian Journal of Surgery, vol. 74, no. 1, pp. 91–99, 2012. View at Publisher · View at Google Scholar · View at Scopus
  203. K. Almhanna, S. Kalmadi, R. Pelley, and R. Kim, “Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?” Oncology, vol. 21, no. 9, pp. 1116–1122, 2007. View at Google Scholar · View at Scopus
  204. T. J. Vogl, N. N. Naguib, N.-E. Nour-Eldin et al., “Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications,” European Journal of Radiology, vol. 72, no. 3, pp. 505–516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  205. M. Lesurtel, B. Müllhaupt, B. C. Pestalozzi, T. Pfammatter, and P.-A. Clavien, “Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence-based analysis,” The American Journal of Transplantation, vol. 6, no. 11, pp. 2644–2650, 2006. View at Publisher · View at Google Scholar · View at Scopus
  206. I. W. Graziadei, H. Sandmueller, P. Waldenberger et al., “Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome,” Liver Transplantation, vol. 9, no. 6, pp. 557–563, 2003. View at Publisher · View at Google Scholar · View at Scopus
  207. G. Millonig, I. W. Graziadei, M. C. Freund et al., “Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma,” Liver Transplantation, vol. 13, no. 2, pp. 272–279, 2007. View at Publisher · View at Google Scholar · View at Scopus
  208. G. Otto, S. Herber, M. Heise et al., “Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma,” Liver Transplantation, vol. 12, no. 8, pp. 1260–1267, 2006. View at Publisher · View at Google Scholar · View at Scopus
  209. M. Ravaioli, G. L. Grazi, F. Piscaglia et al., “Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria,” The American Journal of Transplantation, vol. 8, no. 12, pp. 2547–2557, 2008. View at Publisher · View at Google Scholar · View at Scopus
  210. W. de Luna, D. Y. Sze, A. Ahmed et al., “Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation,” The American Journal of Transplantation, vol. 9, no. 5, pp. 1158–1168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  211. J. W. Jang, C. R. You, C. W. Kim et al., “Benefit of downsizing hepatocellular carcinoma in a liver transplant population,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 3, pp. 415–423, 2010. View at Publisher · View at Google Scholar · View at Scopus
  212. L. de Carlis, S. D. Sandro, A. Giacomoni et al., “Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation?” Journal of Clinical Gastroenterology, vol. 46, no. 1, pp. 78–86, 2012. View at Publisher · View at Google Scholar · View at Scopus
  213. A. Kornberg, U. Witt, E. Matevossian et al., “Extended postinterventional tumor necrosis-implication for outcome in liver transplant patients with advanced HCC,” PloS ONE, vol. 8, no. 1, Article ID e53960, 2013. View at Google Scholar
  214. H. W. Park, S. Hwang, C. S. Ahn et al., “Long-term survival outcomes for living-donor liver transplant recipients with pathologically nonviable hepatocellular carcinoma,” Transplantation Proceedings, vol. 45, no. 8, pp. 3032–3034, 2013. View at Google Scholar
  215. M. A. Machado, F. F. Makdissi, and R. C. Surjan, “Right trisectionectomy with principle en bloc portal vein resection for right-sided hilar cholangiocarcinoma: no-touch technique,” Annals of Surgical Oncology, vol. 18, no. 4, pp. 1324–1325, 2012. View at Publisher · View at Google Scholar · View at Scopus
  216. S. Agrawal and J. Belghiti, “Oncologic resection for malignant tumors of the liver,” Annals of Surgery, vol. 253, no. 4, pp. 656–665, 2011. View at Publisher · View at Google Scholar · View at Scopus
  217. R. C. Grant, L. Sandhu, P. R. Dixon et al., “Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis,” Clinical Transplantation, vol. 27, no. 1, pp. 140–147, 2013. View at Google Scholar
  218. T. Kaido and S. Uemoto, “Does living donation have advantages over deceased donation in liver transplantation?” Journal of Gastroenterology and Hepatology, vol. 25, no. 10, pp. 1598–1603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  219. K. Tanaka, Y. Ogura, T. kiuchi et al., “Living donor liver transplantation: eastern experiences,” HPB, vol. 6, no. 2, pp. 88–89, 2004. View at Google Scholar
  220. S. Lobritto, T. Kato, J. Emond et al., “Living-donor liver transplantation: current perspective,” Seminars in Liver Disease, vol. 32, no. 4, pp. 333–340, 2012. View at Google Scholar
  221. X. Q. Liu, Z. Q. Hu, Y. F. Pei, and R. Tao, “Clinical operational tolerance in liver transplantation: state-of-the-art perspective and future prospects,” Hepatobiliary Pancreatic Diseasees International, vol. 12, no. 1, pp. 12–33, 2013. View at Google Scholar
  222. C. E. Broelsch, M. Malago, A. Frilling et al., “Living donor liver transplantation,” Chirurg, vol. 79, no. 2, pp. 135–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
  223. S. Florman and C. M. Miller, “Live donor liver transplantation,” Liver Transplantation, vol. 12, no. 4, pp. 499–510, 2006. View at Publisher · View at Google Scholar · View at Scopus
  224. C. M. Lo, S. T. Fan, C. L. Liu, S. C. Chan, I. O.-L. Ng, and J. Wong, “Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma,” British Journal of Surgery, vol. 94, no. 1, pp. 78–86, 2007. View at Publisher · View at Google Scholar · View at Scopus
  225. R. A. Fisher, L. M. Kulik, C. E. Freise et al., “Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation,” The American Journal of Transplantation, vol. 7, no. 6, pp. 1601–1608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  226. P. Bhangui, E. Vibert, P. Majno et al., “Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation,” Hepatology, vol. 53, no. 5, pp. 1570–1579, 2011. View at Publisher · View at Google Scholar · View at Scopus
  227. W. Liang, L. Wu, X. Ling et al., “Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma: a meta-analysis,” Liver Transplantation, vol. 18, no. 10, pp. 1226–1236, 2012. View at Google Scholar
  228. R. C. Grant, L. Sandhu, P. R. Dixon et al., “Living vs. deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis,” Clinical Transplantation, vol. 27, no. 1, pp. 140–147, 2013. View at Google Scholar
  229. S. Todo, H. Furukawa, R. W. Busuttil, C. Miller, and C. Broelsch, “Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan,” Annals of Surgery, vol. 240, no. 3, pp. 451–461, 2004. View at Publisher · View at Google Scholar · View at Scopus
  230. K. Shirabe, A. Taketomi, K. Morita et al., “Comparative evaluation of expanded criteria for patients with hepatocellular carcinoma beyond the Milan criteria undergoing living-related donor liver transplantation,” Clinical Transplantation, vol. 25, no. 5, pp. E491–E498, 2011. View at Publisher · View at Google Scholar · View at Scopus
  231. D. Balci, M. Dayangac, O. Yaprak et al., “Living donor liver transplantation for hepatocellular carcinoma: a single center analysis of outcomes and impact of different selection criteria,” Transplant International, vol. 24, no. 11, pp. 1075–1083, 2011. View at Publisher · View at Google Scholar · View at Scopus
  232. Y. Zhai, H. Petrowsky, J. C. Hong et al., “Ischaemia-reperfusion injury in liver transplantation–from bench to bedside,” Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 2, pp. 79–89, 2013. View at Google Scholar
  233. I. Hilmi, C. N. Horton, R. M. Planinsic et al., “The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation,” Liver Transplantation, vol. 14, no. 4, pp. 504–508, 2008. View at Publisher · View at Google Scholar · View at Scopus
  234. J. D. W. van der Bilt, O. Kranenburg, M. W. Nijkamp et al., “Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model,” Hepatology, vol. 42, no. 1, pp. 165–175, 2005. View at Publisher · View at Google Scholar · View at Scopus
  235. J. D. W. van der Bilt, O. Kranenburg, A. Borren, R. van Hillegersberg, and I. H. M. Borel Rinkes, “Ageing and hepatic steatosis exacerbate ischemia/reperfusion-accelerated outgrowth of colorectal micrometastases,” Annals of Surgical Oncology, vol. 15, no. 5, pp. 1392–1398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  236. K. Man, K. T. Ng, C. M. Lo et al., “Ischemia-reperfusion of small liver remnant promotes liver tumor growth and metastases—activation of cell invasion and migration pathways,” Liver Transplantation, vol. 13, no. 12, pp. 1669–1677, 2007. View at Publisher · View at Google Scholar · View at Scopus
  237. K. Man, C. M. Lo, J. W. Xiao et al., “The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation,” Annals of Surgery, vol. 247, no. 6, pp. 1049–1057, 2008. View at Publisher · View at Google Scholar · View at Scopus
  238. C. C. Ling, K. T. Ng, Y. Shao et al., “Post-transplant endothelial progenitor cell mobilization via CXCL10/CXCR3 signaling promotes liver tumor growth,” Journal of Hepatology, vol. 60, no. 1, pp. 103–109, 2014. View at Publisher · View at Google Scholar
  239. K. P. Croome, W. Wall, N. Chandok et al., “Inferior survival in liver transplant recipients with hepatocellular carcinoma receiving donation after cardiac death liver allografts,” Liver Transplantation, 2013. View at Publisher · View at Google Scholar
  240. A. H. Elaffandi, G. K. Bonney, B. Gunson et al., “Increasing the donor pool: consideration of prehospital cardiac arrest in controlled donation after circulatory death for liver transplantation,” Liver Transplantation, vol. 20, no. 1, pp. 63–71, 2014. View at Publisher · View at Google Scholar
  241. A. Kornberg, B. Küpper, A. Tannapfel et al., “Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables,” European Journal of Surgical Oncology, vol. 36, no. 3, pp. 275–280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  242. I. Yokoyama, B. Carr, H. Saitsu, S. Iwatsuki, and T. E. Starzl, “Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation,” Cancer, vol. 68, no. 10, pp. 2095–2100, 1991. View at Google Scholar · View at Scopus
  243. J. P. Roberts, “Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation,” Liver Transplantation, vol. 11, no. S2, pp. S45–S46, 2005. View at Publisher · View at Google Scholar · View at Scopus
  244. A. L. B. Benson III, T. A. Abrams, E. Ben-Josef et al., “NCCN clinical practice guidelines in oncology: hepatobiliary cancers,” Journal of the National Comprehensive Cancer Network, vol. 7, no. 4, pp. 350–391, 2009. View at Google Scholar · View at Scopus
  245. S. N. Sherston, R. P. Carroll, P. N. Harden, and K. J. Wood, “Predictors of cancer risk in the long-term solid-organ transplant recipient,” Transplantation, 2013. View at Publisher · View at Google Scholar
  246. S. Masuda and K.-I. Inui, “An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients,” Pharmacology and Therapeutics, vol. 112, no. 1, pp. 184–198, 2006. View at Publisher · View at Google Scholar · View at Scopus
  247. J. Dantal, M. Hourmant, D. Cantarovich et al., “Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens,” The Lancet, vol. 351, no. 9103, pp. 623–628, 1998. View at Publisher · View at Google Scholar · View at Scopus
  248. C. E. Freise, L. Ferrell, T. Liu, N. L. Ascher, and J. P. Roberts, “Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma,” Transplantation, vol. 67, no. 4, pp. 510–513, 1999. View at Google Scholar · View at Scopus
  249. M. Vivarelli, R. Bellusci, A. Cucchetti et al., “Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression?” Transplantation, vol. 74, no. 12, pp. 1746–1751, 2002. View at Google Scholar · View at Scopus
  250. M. Vivarelli, A. Cucchetti, F. Piscaglia et al., “Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression,” Liver Transplantation, vol. 11, no. 5, pp. 497–503, 2005. View at Publisher · View at Google Scholar · View at Scopus
  251. M. Vivarelli, A. Cucchetti, G. L. Barba et al., “Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence,” Annals of Surgery, vol. 248, no. 5, pp. 857–862, 2008. View at Publisher · View at Google Scholar · View at Scopus
  252. M. Rodríguez-Perálvarez, E. Tsochatzis, M. C. Naveas et al., “Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma,” Journal of Hepatology, vol. 59, no. 6, pp. 1193–1199, 2013. View at Google Scholar
  253. T. Xing, L. Huang, and Z. Yu, “Comparison of steroid-free immunosuppression and standard immunosuppression for liver transplant patients with hepatocellular carcinoma,” PLoS ONE, vol. 8, no. 8, Article ID e71251, 2013. View at Google Scholar
  254. A. P. Monaco, “The role of mTOR inhibitors in the management of posttransplant malignancy,” Transplantation, vol. 87, no. 2, pp. 157–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  255. C. A. Witt and R. R. Hachem, “Immunosuppression: what's standard and what's new?” Seminars in Respiratory and Critical Care Medicine, vol. 34, no. 3, pp. 405–413, 2013. View at Google Scholar
  256. P. F. Halloran, “Molecular mechanisms of new immunosuppressants,” Clinical Transplantation, vol. 10, no. 1, part 2, pp. 118–123, 1996. View at Google Scholar · View at Scopus
  257. M. Kudo, “Molecular targeted therapy for hepatocellular carcinoma: bench to bedside,” Digestive Diseases, vol. 29, no. 3, pp. 273–277, 2011. View at Publisher · View at Google Scholar · View at Scopus
  258. O. Bestard, J. M. Cruzado, and J. M. Grinyó, “Calcineurin-inhibitor-sparing immunosuppressive protocols,” Transplantation Proceedings, vol. 37, no. 9, pp. 3729–3732, 2005. View at Publisher · View at Google Scholar · View at Scopus
  259. M. Vivarelli, A. Dazzi, M. Zanello et al., “Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma,” Transplantation, vol. 89, no. 2, pp. 227–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  260. C. Toso, S. Merani, D. L. Bigam, A. M. J. Shapiro, and N. M. Kneteman, “Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma,” Hepatology, vol. 51, no. 4, pp. 1237–1243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  261. W. Liang, D. Wang, X. Ling et al., “Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis,” Liver Transplantation, vol. 18, no. 1, pp. 62–69, 2012. View at Publisher · View at Google Scholar · View at Scopus
  262. K. V. Menon, A. R. Hakeem, and N. D. Heaton, “Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma,” Alimentary Pharmacology and Therapeutics, vol. 37, no. 4, pp. 411–419, 2013. View at Google Scholar
  263. K. M. Olthoff, M. H. Rosove, C. R. Shackleton et al., “Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma,” Annals of Surgery, vol. 221, no. 6, pp. 734–741, 1995. View at Google Scholar · View at Scopus
  264. S. Roayaie, J. S. Frischer, S. H. Emre et al., “Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters,” Annals of Surgery, vol. 235, no. 4, pp. 533–539, 2002. View at Publisher · View at Google Scholar · View at Scopus
  265. Z. G. Wang, G. F. Zhang, J. C. Wu, and M. K. Jia, “Adjuvant therapy for hepatocellular carcinoma: current situation and prospect,” Drug Discoveries and Therapeutics, vol. 7, no. 4, pp. 137–143, 2013. View at Google Scholar
  266. M. Fujiki, F. Aucejo, and R. Kim, “Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?” Clinical Transplantation, vol. 27, no. 2, pp. 169–177, 2013. View at Google Scholar
  267. Y.-S. Guan and Q. He, “Sorafenib: activity and clinical application in patients with hepatocellular carcinoma,” Expert Opinion on Pharmacotherapy, vol. 12, no. 2, pp. 303–313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  268. S. Saab, M. McTigue, R. S. Finn, and R. W. Busuttil, “Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy,” Experimental and Clinical Transplantation, vol. 8, no. 4, pp. 307–313, 2010. View at Google Scholar · View at Scopus
  269. C.-L. Teng, W.-L. Hwang, Y.-J. Chen, K.-H. Chang, and S.-B. Cheng, “Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study,” World Journal of Surgical Oncology, vol. 10, article 41, 2012. View at Publisher · View at Google Scholar · View at Scopus
  270. N. Li, J. Zhou, D. Weng et al., “Adjuvant adenovirus-mediated delivery of herpes simplex virus thymidine kinase administration improves outcome of liver transplantation in patients with advanced hepatocellular carcinoma,” Clinical Cancer Research, vol. 13, no. 19, pp. 5847–5854, 2007. View at Publisher · View at Google Scholar · View at Scopus